Twitter Facebook LinkedIn YouTube

HLS Therapeutics Inc. (TSXV:HLS) New Listing

Video Platform Video Management Video Solutions Video Player

HLS Therapeutics is a specialty pharmaceutical company acquiring and distributing commercial stage or established, branded pharmaceutical drugs for the North American markets

Additional Information:

Company: HLS Therapeutics Inc.
Website: http://www.HLStherapeutics.com
Stock Symbol: TSXV: HLS
Date Published: Mar 15, 2018
Transcript: Available

Video Transcript:

I’m Samantha Deutscher for Investmentpitch Media

HLS Therapeutics Inc. is one the latest new listings on the TSX Venture Exchange, trading under the symbol “HLS”, having previously traded as Automodular Corporation under the symbol “AMD”, prior to a reverse takeover.

HLS Therapeutics is a specialty pharmaceutical company acquiring and distributing commercial stage or established, branded pharmaceutical drugs for the North American markets.

The company sources its products from the drug’s originator or from best-in-class manufacturing partners, ensuring its brands are manufactured with the highest standards of quality and in compliance with FDA and Health Canada’s regulations.

The company’s focus is primarily on products targeting the central nervous system and cardiovascular therapeutic areas.

The management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.

The management team has executed over US$8 billion worth of transactions in the specialty pharmaceutical space, and devised and led the turnaround of Biovail Corporation, at the time Canada’s largest publicly traded pharmaceutical company.

Greg Gubitz, CEO, stated: “This is a proud and exciting day for all of us at HLS. In just over two years we have assembled an experienced team with a focused strategy, generated solid growth with strong financial margins, and most importantly, we have built a portfolio that is positioned to deliver positive healthcare outcomes and enhance the lives of thousands of patients each day. We believe we have a unique and scalable strategy for building a specialty pharmaceutical company, which by focusing first on the patient will ultimately drive value creation for shareholders and growth opportunity for employees.”

The company is looking for additional opportunities in the pharma market to build its commercial portfolio.

The shares are trading at $11.50.

For more information, please visit the company’s website at www.HLStherapeutics.com, contact Gilbert Godin, President and COO, at 484-232-3400 ext 101, or email g.godin@HLStherapeutics.com.

Investor relations is handled by Ross Marshall at LodeRock Advisors, who can be reached at 416-526-1563 or email ross.marshall@loderockadvisors.com.

I’m Samantha Deutscher for Investmentpitch Media